ES2429406T3 - Cannabinoides para su uso en el tratamiento del dolor neuropático - Google Patents

Cannabinoides para su uso en el tratamiento del dolor neuropático Download PDF

Info

Publication number
ES2429406T3
ES2429406T3 ES07733311T ES07733311T ES2429406T3 ES 2429406 T3 ES2429406 T3 ES 2429406T3 ES 07733311 T ES07733311 T ES 07733311T ES 07733311 T ES07733311 T ES 07733311T ES 2429406 T3 ES2429406 T3 ES 2429406T3
Authority
ES
Spain
Prior art keywords
thc
cbd
embc
pain
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07733311T
Other languages
English (en)
Spanish (es)
Inventor
Geoffrey Guy
Barbara Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Application granted granted Critical
Publication of ES2429406T3 publication Critical patent/ES2429406T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES07733311T 2006-06-23 2007-06-21 Cannabinoides para su uso en el tratamiento del dolor neuropático Active ES2429406T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612512A GB2439393B (en) 2006-06-23 2006-06-23 Cannabinoids for use in the treatment of neuropathic pain
GB0612512 2006-06-23
PCT/GB2007/002315 WO2007148094A1 (en) 2006-06-23 2007-06-21 Cannabinoids for use in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
ES2429406T3 true ES2429406T3 (es) 2013-11-14

Family

ID=36803806

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07733311T Active ES2429406T3 (es) 2006-06-23 2007-06-21 Cannabinoides para su uso en el tratamiento del dolor neuropático

Country Status (8)

Country Link
US (3) US20100016418A1 (enExample)
EP (1) EP2037902B1 (enExample)
JP (2) JP5399898B2 (enExample)
CA (1) CA2656698C (enExample)
ES (1) ES2429406T3 (enExample)
GB (1) GB2439393B (enExample)
PL (1) PL2037902T3 (enExample)
WO (1) WO2007148094A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
JP2010535238A (ja) 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2934512B1 (en) 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
BR112016024488A2 (pt) * 2014-04-21 2017-08-15 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd compostos de ciclo-hexenila, composições que compreendem esses e o uso dos mesmos
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
US10406186B2 (en) * 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
AU2016269328A1 (en) 2015-05-28 2017-12-07 Tweed Inc. Cannabis plants having modified expression of THCA synthase
AU2016359160A1 (en) * 2015-11-24 2018-06-14 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3676238A1 (en) * 2017-09-01 2020-07-08 Pureform Global, Inc. Synthetic cannabidiol compositions and methods of making the same
EP3681525A4 (en) * 2017-09-15 2020-09-02 Zelda Therapeutics Operations Pty Ltd COMPOSITION AND METHOD OF PROCESSING AUTISM
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
US20190183849A1 (en) * 2017-10-21 2019-06-20 Alexander Kariman Compound and method for treatment of diseases and disorders
US20200315933A1 (en) * 2017-12-20 2020-10-08 Hanyi Bio-Technology Company Ltd. Use of cannabidiol or cannabis extract in preparation of skin whitening products
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
SI25373A (sl) * 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
BR112020025628A2 (pt) * 2018-06-15 2021-03-23 CannPal Animal Therapeutics Limited composição de canabinóide e métodos de tratamento usando o mesmo
CA3111788A1 (en) * 2018-09-05 2020-03-12 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
AU2020264426A1 (en) * 2019-05-01 2022-01-06 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021070120A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12097293B2 (en) 2019-10-14 2024-09-24 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN114667135A (zh) * 2019-11-07 2022-06-24 艾美锐思公司 用于向皮肤递送大麻素的组合物和方法
WO2022006187A1 (en) * 2020-06-30 2022-01-06 Np Pharma Holdings, Llc Methods of using cannabinoid compositions for inducing and promoting sleep
US11478446B2 (en) 2020-08-28 2022-10-25 Teresa Ann HANLON Pain relieving formulations containing cannabis and methods of making same
WO2022159507A1 (en) * 2021-01-19 2022-07-28 Merit Therapeutics, Inc. Combination of cannabinoids with additional therapeutic agents for treating diseases or disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
MXPA03007215A (es) * 2001-02-14 2003-12-04 Gw Pharma Ltd Formulaciones farmaceuticas.
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
AU2003253005B2 (en) * 2002-08-14 2009-03-19 Jazz Pharmaceuticals Research Uk Limited Cannabinoid liquid formulations for mucosal administration
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain

Also Published As

Publication number Publication date
EP2037902B1 (en) 2013-07-03
US20100016418A1 (en) 2010-01-21
GB0612512D0 (en) 2006-08-02
US20120245224A1 (en) 2012-09-27
CA2656698C (en) 2015-10-13
US20190224140A1 (en) 2019-07-25
JP2013241471A (ja) 2013-12-05
GB2439393A (en) 2007-12-27
JP2009541479A (ja) 2009-11-26
JP5399898B2 (ja) 2014-01-29
WO2007148094A1 (en) 2007-12-27
CA2656698A1 (en) 2007-12-27
PL2037902T3 (pl) 2013-12-31
GB2439393B (en) 2011-05-11
EP2037902A1 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
ES2429406T3 (es) Cannabinoides para su uso en el tratamiento del dolor neuropático
JP6147249B2 (ja) 神経因性疼痛の治療において使用するためのカンナビノイド
AU2015341458B2 (en) Methods for treatment of cognitive decline
Rahmati et al. Anti-epileptogenic and antioxidant effect of Lavandula officinalis aerial part extract against pentylenetetrazol-induced kindling in male mice
Hayman et al. Capsaicin: A review of its pharmacology and clinical applications
US20100035978A1 (en) Combination of cannabinoids for the treatment of peripheral neuropathic pain
ZA200610242B (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
CA3000918A1 (en) Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality
Blebea et al. EVALUATION OF THERAPEUTIC POTENTIAL OF CANNABIDIOLBASED PRODUCTS IN ANIMAL MODELS OF EPILEPTIC SEIZURES, NEUROPATHIC PAIN AND CHRONIC INFLAMMATION.
Bharathi et al. Plants and their derivatives as potential source in treatment of alcohol withdrawal syndrome and other treatment strategies: A review
US11395813B1 (en) Cannabinoids based pharmaceutical composition
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
Jain Study of herbal drugs for the treatment of sexual dysfunction
Nouri et al. Gabaergic system role in aqueous extract of Valeriana officinalis L. root on PTZ-induced clonic seizure threshold in mice
Gupta et al. Review on Impact of natural plant products on computer vision syndrome
de la Pena et al. Supplementation of Laurus nobilis attenuate ethanol-induced psychomotor alterations in rats
WO2014184398A1 (es) Formula farmacéutica para el tratamiento de afecciones que involucran al sistema venoso y linfático, al sobrepeso y la obesidad
Bedard Kava: the root to happiness?
ES2464692A1 (es) Composición para la mejora de la respuesta sexual femenina